Today: 21 May 2026
Cisco stock price today: CSCO slips as Wall Street frets rates and Cisco pushes new AI security tools
30 January 2026
2 mins read

Cisco stock price today: CSCO slips as Wall Street frets rates and Cisco pushes new AI security tools

New York, Jan 30, 2026, 14:19 (EST) — Regular session

  • CSCO slipped about 1.1% earlier but pared losses to trade down 0.2% in early afternoon action
  • Rate jitters resurfaced following a hotter-than-expected U.S. wholesale inflation report and news of a new Fed chair nominee
  • In the last 24 hours, Cisco unveiled new AI-driven security tools and released updated threat research

Cisco Systems shares slipped 0.2% to $78.31 in early afternoon trading Friday, after dropping as much as 1.1% earlier. Arista Networks declined 2.5%, while Palo Alto Networks edged up 0.8%.

Wall Street pulled back cautiously after Donald Trump nominated Kevin Warsh to head the Federal Reserve once Jerome Powell’s term expires, combined with hotter-than-expected producer-price data. “It’s hard to know exactly what direction Warsh will go because he’s had a past history of being a hawk,” Eric Gerster of AlphaCore Wealth Advisory told Reuters. Reuters

Days like this still hold weight for Cisco. As a bellwether for corporate network and security budgets, its stock often reacts sharply, even if the headlines focus mainly on products and roadmaps. Big tech names tend to catch the brunt when rates fluctuate.

Cisco’s recent news has focused heavily on security and “AI-native” tools—areas investors are watching closely as companies look to protect new AI workloads without boosting staff numbers. The real test isn’t the demos, but whether these efforts translate into higher renewal rates, software attach, and backlog growth.

On Thursday, Cisco’s Foundation AI team unveiled a new “open-weight” security reasoning model, making the underlying weights downloadable and runnable rather than restricted to a closed API. Yaron Singer described the model as “purpose-built for cybersecurity workflows.” Cisco confirmed the model is now available on Hugging Face. Cisco Blogs

An industry report on Friday revealed Cisco is integrating the model with “agentic AI” — software built to perform multi-step tasks instead of just responding to prompts — to accelerate investigations within security operations centers, or SOCs. The fine-tuned release is based on Meta Platforms’s Llama model, the report added. SDxCentral

Cisco’s threat intelligence division backed up its broader claims with specific data. In a blog post released Thursday, Cisco Talos reported that nearly 40% of its incident-response cases in the fourth quarter involved exploitation of public-facing applications. Phishing ranked second, the post noted, while warning that attackers wasted no time acting on newly disclosed vulnerabilities.

Cisco is ramping up its policy management tools. According to a Network World report Thursday, the company plans to roll out its Mesh Policy Engine next month within Security Cloud Control. This aims to let customers define security intent once, then push policies across Cisco and third-party firewalls, including Palo Alto and others. “The traditional approach … places a lot of overhead on the network operator,” Murali Rathinasamy wrote in a Cisco blog cited by the story.

The stock barely moved. That could mean the market had already factored in steady execution, or investors might be holding out for clear evidence that the security and AI stack is driving billings—not just showing promise in lab results.

There’s a risk angle too. Open-weight releases often draw attention to guardrails, compliance, and customer deployment practices. On top of that, the market’s been edgy over inflation and the direction of interest rates, which could ripple into enterprise IT spending.

Investors face a key date on Feb. 11, when Cisco reports its fiscal second-quarter results in the next quarterly call; that period ended Jan. 24.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Johnson & Johnson stock today: JNJ steadies after talc court win, EU panel backs AKEEGA expansion
Previous Story

Johnson & Johnson stock today: JNJ steadies after talc court win, EU panel backs AKEEGA expansion

Joby Aviation stock drops again as $1.2 billion capital raise puts dilution back in focus
Next Story

Joby Aviation stock drops again as $1.2 billion capital raise puts dilution back in focus

Go toTop